Sorry... 3 kids at home for school, work calls, listening, and taking notes, so i was unable to post until now.
DJ did a great job w the summary of prepared comments. Here are my additional thoughts on that and my Qs:
1). Failure of the first agreement w China appears to have set us back on peptide/convalescent blood testing (and no activity from the Chinese side, including payment, ever occurred). So testing is back on track thru a new testing center. No timeline given for completion.
2). NGIO Form 10 accepted, still dealing w SEC comments. No delays on our side. Once comments are cleared, S-1 will be submitted.
3). Covid vaccine IND still intended to be filed this year if possible, so a Feb start for a clinical trial is possible as well.
4). NuGenHealth - app/portal is existing and seamless. 1000 patients currently using the system. At home diagnostics/monitoring uses Bluetooth. Covid interrupted supply of devices, but should have some in 4-6 weeks. Will begin enrolling AZ patients immediately... hopefully will be up to 5000 in 6 months. Payment cycle from service to money in the bank is about 30-35 days. So receipt revenue realistic in 3 months.
Also negotiating w an EMR... would be the only group integrating that piece.
This seems to me like a fantastic opportunity and could provide a real, growing, continuous revenue stream.
5). MSO still nowhere without funding.
6). BARDA - I don’t think there was anything fishy about this discussion. The application was massive. They took their time to do DD on it, asked for some items. Joe and team got 2 of 3 to them (pre-IND and 3M safety data) and will add the missing link of peptide/convalescent blood testing when it is available.
7). Excellagen - May have 25% VA capacity soon, so maybe can limp out of the gate again. Interviewing a lot of sales force candidates. Focusing on retired people who might want 1099 work and have experience w VA and/or wound care. Sounds good... can work a little if that is what is available or full-bore once VA is more accessible.
. Regentys - working on approvals. Setting up Australia trial for Q1. I jogged a lot of Qs and couldn’t get in to clarify if that’s Q1 fiscal or calendar, but I assume calendar.
9). Diagnostic acquisition - nucleus acid test. Identifies 4 genes instead of 2, like most tests do. So fewer false +/- results. Can be used w different testing methods, unlike other tests. Working on home-based kit. I believe the target co is Aima Bio, but haven’t looked it up. I wish someone smarter than me would have asked some Qs on this topic...
10). Non-BARDA Covid deals seem great if we can secure one or more. Setup w up front payments and funding for development are our only real option without NGIO listing funds for now.
11). Altucell seems to be moving forward where they can, with S American study, regulatory, human, Italian transplant study (waiting for start date). Might have a market for outsourcing the encapsulation study.
All in all, I think we are where we thought we were, except this NuGenHealth could be an added and lucrative near-term opportunity.
Interesting that Joe didn’t mention tomorrow’s call at the close...
DJ did a great job w the summary of prepared comments. Here are my additional thoughts on that and my Qs:
1). Failure of the first agreement w China appears to have set us back on peptide/convalescent blood testing (and no activity from the Chinese side, including payment, ever occurred). So testing is back on track thru a new testing center. No timeline given for completion.
2). NGIO Form 10 accepted, still dealing w SEC comments. No delays on our side. Once comments are cleared, S-1 will be submitted.
3). Covid vaccine IND still intended to be filed this year if possible, so a Feb start for a clinical trial is possible as well.
4). NuGenHealth - app/portal is existing and seamless. 1000 patients currently using the system. At home diagnostics/monitoring uses Bluetooth. Covid interrupted supply of devices, but should have some in 4-6 weeks. Will begin enrolling AZ patients immediately... hopefully will be up to 5000 in 6 months. Payment cycle from service to money in the bank is about 30-35 days. So receipt revenue realistic in 3 months.
Also negotiating w an EMR... would be the only group integrating that piece.
This seems to me like a fantastic opportunity and could provide a real, growing, continuous revenue stream.
5). MSO still nowhere without funding.
6). BARDA - I don’t think there was anything fishy about this discussion. The application was massive. They took their time to do DD on it, asked for some items. Joe and team got 2 of 3 to them (pre-IND and 3M safety data) and will add the missing link of peptide/convalescent blood testing when it is available.
7). Excellagen - May have 25% VA capacity soon, so maybe can limp out of the gate again. Interviewing a lot of sales force candidates. Focusing on retired people who might want 1099 work and have experience w VA and/or wound care. Sounds good... can work a little if that is what is available or full-bore once VA is more accessible.
. Regentys - working on approvals. Setting up Australia trial for Q1. I jogged a lot of Qs and couldn’t get in to clarify if that’s Q1 fiscal or calendar, but I assume calendar. 9). Diagnostic acquisition - nucleus acid test. Identifies 4 genes instead of 2, like most tests do. So fewer false +/- results. Can be used w different testing methods, unlike other tests. Working on home-based kit. I believe the target co is Aima Bio, but haven’t looked it up. I wish someone smarter than me would have asked some Qs on this topic...
10). Non-BARDA Covid deals seem great if we can secure one or more. Setup w up front payments and funding for development are our only real option without NGIO listing funds for now.
11). Altucell seems to be moving forward where they can, with S American study, regulatory, human, Italian transplant study (waiting for start date). Might have a market for outsourcing the encapsulation study.
All in all, I think we are where we thought we were, except this NuGenHealth could be an added and lucrative near-term opportunity.
Interesting that Joe didn’t mention tomorrow’s call at the close...
9
